All Posts

SUMMARY Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation...

Summary Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation included expanded data from the Phase 1a/1b trial expansion cohort in MSS-CRC Key publicly available data from the presentation is provided below. Want more AGEN analysis and trade ideas? Sign up for one of our paid subscriptions HERE  and save with our current promotion Sign up for a BPIQ Pro account and get access to our BPIQ Pro post HERE , with

Article being drafted Summary Recently we posted an article about the AGEN readout at ASCO-GI for its lead asset botensilimab  (anti-CTLA-4) in combination with AGEN's anti-PD1 (balstilimab): Here's a link to our prior post  which provides detailed background information. The ASCO-GI23 presentation included expanded data from the Phase 1a/1b trial expansion cohort Key publicly available data from the presentation is provided below. If you are an Amp Pro subscriber, read our c

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst...

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst readouts . See below for a table full of major events you should keep an eye on that are expected in the coming weeks. BPIQ Weekly Catalyst Watchlist Table: Weekly Watchlist Highlights: CDTX - Cidara Therapeutics Inc   Cidara has an Adcom meeting on 1/24/23 for their drug Rezafungin for the treatment of candidemia and invasive candidiasis. The NDA s

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

First posted 1/19/2023; last updated 3/1/23 Summary Every month we identify biotech Big-Mover stocks and Movers to Watch stocks, with key upcoming clinical trial readouts. These "Mover" stock lists are intended to help biopharma investors because they provide a heads-up that these stocks, which might be in an investor's portfolio, are likely to see a big price move, and usually these price moves are negative. Our initial February Biotech Big-Mover Stocks includes 3  companies

Summary Recently we posted an article about upcoming gastro readouts including those at ASCO-GI and the upcoming MRK & SGEN PDUFA - HERE   One readout coming at ASCO-GI is from AGEN's lead asset botensilimab  (anti-CTLA-4) in combination with AGEN's anti-PD1 (balstilimab) Botensilimab is currently in a Phase 2 trial, and the ASCO-GI presentation will include expanded data from the Phase 1a/1b trial expansion cohort Here we look at how the Bot/Bal combo data has looked in the

Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal...

Article currently in progress (1/17/23) Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal cancer, esophageal cancer, and colorectal cancer ( https://conferences.asco.org/gi/program ) In past years, big readouts have happened at this conference including from several Phase 3 trials On Thursday Jan 19 there is also a PDUFA for a GI indication: the SGEN and MRK PDUFA for Tukysa (Tucatinib) to